P F Smith

Summary

Affiliation: University at Buffalo
Country: USA

Publications

  1. ncbi request reprint Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model
    Patrick F Smith
    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Applied Pharmacodynamics Laboratory, Department of Pharmacy Practice, Buffalo, NY 14260, USA
    Diagn Microbiol Infect Dis 56:379-86. 2006
  2. pmc Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
  3. ncbi request reprint Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center
    Patrick F Smith
    Applied Pharmacodynamics Laboratory, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY 14260, USA
    Diagn Microbiol Infect Dis 52:255-9. 2005
  4. ncbi request reprint Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals
    Patrick F Smith
    Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
    Clin Pharmacokinet 44:99-109. 2005
  5. ncbi request reprint Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone
    Patrick F Smith
    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, New York 14260, USA
    Pharmacotherapy 24:970-7. 2004
  6. ncbi request reprint Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
    P F Smith
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Ann Oncol 14:795-801. 2003
  7. pmc Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans
    P F Smith
    The State University of New York at Buffalo School of Pharmacy, Millard Fillmore Hospital, Buffalo, New York, USA
    Antimicrob Agents Chemother 44:1609-15. 2000
  8. ncbi request reprint Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors
    P F Smith
    Laboratory for Antiviral Research, University at Buffalo, The State University of New York School of Pharmacy and Pharmaceutical Sciences, Amherst, New York 14260, USA
    Clin Pharmacokinet 40:893-905. 2001
  9. ncbi request reprint Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients
    P F Smith
    School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 14260, USA
    Clin Ther 23:1231-44. 2001
  10. pmc Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males
    P F Smith
    The State University of New York at Buffalo School of Pharmacy, Millard Fillmore Hospital, Buffalo, New York, USA
    Antimicrob Agents Chemother 44:2816-23. 2000

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model
    Patrick F Smith
    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Applied Pharmacodynamics Laboratory, Department of Pharmacy Practice, Buffalo, NY 14260, USA
    Diagn Microbiol Infect Dis 56:379-86. 2006
    ..influenzae. Consistent with limited clinical data, a minimum %T > MIC of 40% to 50% would be suggested to achieve in vivo activity in otitis media, with maximal activity at approximately 70%T > MIC...
  2. pmc Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
    ..There were no significant differences in efavirenz pharmacokinetics...
  3. ncbi request reprint Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center
    Patrick F Smith
    Applied Pharmacodynamics Laboratory, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY 14260, USA
    Diagn Microbiol Infect Dis 52:255-9. 2005
    ..Future clinical studies to evaluate a potential role for these agents in the management of infections in cancer patients, including the treatment of febrile neutropenia, appear warranted...
  4. ncbi request reprint Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals
    Patrick F Smith
    Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
    Clin Pharmacokinet 44:99-109. 2005
    ..Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies...
  5. ncbi request reprint Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone
    Patrick F Smith
    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, New York 14260, USA
    Pharmacotherapy 24:970-7. 2004
    ..To evaluate the potential effect of tenofovir disoproxil fumarate (DF) on the pharmacokinetics of methadone...
  6. ncbi request reprint Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
    P F Smith
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Ann Oncol 14:795-801. 2003
    ..We evaluated the results of linezolid therapy in neutropenic cancer patients with Gram-positive bacterial infections from a compassionate-use program...
  7. pmc Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans
    P F Smith
    The State University of New York at Buffalo School of Pharmacy, Millard Fillmore Hospital, Buffalo, New York, USA
    Antimicrob Agents Chemother 44:1609-15. 2000
    ..No serious adverse events were reported during the study. These results suggest that dOTC is well absorbed, widely distributed, and well tolerated. The terminal half-lives indicate that dosing intervals of 12 to 24 h would be reasonable...
  8. ncbi request reprint Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors
    P F Smith
    Laboratory for Antiviral Research, University at Buffalo, The State University of New York School of Pharmacy and Pharmaceutical Sciences, Amherst, New York 14260, USA
    Clin Pharmacokinet 40:893-905. 2001
    ..Additional factors such as the influence of food and pH on oral absorption, and protein binding, must also be considered...
  9. ncbi request reprint Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients
    P F Smith
    School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 14260, USA
    Clin Ther 23:1231-44. 2001
    ..Pharmacokinetic/pharmacodynamic (PK/PD) optimization of antibiotic therapy has been shown to improve outcomes in several antibiotic classes. Despite the frequent use of beta-lactams, clinical data in humans remain limited...
  10. pmc Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males
    P F Smith
    The State University of New York at Buffalo School of Pharmacy, Millard Fillmore Hospital, Buffalo, New York, USA
    Antimicrob Agents Chemother 44:2816-23. 2000
    ..6 (20%) (P<0.05). There was no significant effect of dose size on the pharmacokinetics of racemic dOTC. All doses were well tolerated, and no serious adverse events or laboratory abnormalities were observed...
  11. doi request reprint In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus
    Brian T Tsuji
    School of Pharmacy and Pharmaceutical Sciences and The New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, State University of New York, NY 14260, USA
    J Antimicrob Chemother 62:156-60. 2008
    ..We evaluated the in vitro pharmacodynamics and bactericidal activity of ABI-0043 against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA)...
  12. pmc Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype
    Brian T Tsuji
    School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 331 Cooke Hall, Buffalo, NY 14260, USA
    Antimicrob Agents Chemother 52:1533-7. 2008
    ..Vancomycin killing activities against hemB mutants were markedly attenuated, demonstrating approximately 50% less effect, a result which was well described by a Hill-type pharmacodynamic model...
  13. ncbi request reprint Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion
    Patrick F Smith
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Pharmacol 43:1324-8. 2003
    ..Further increases in mesna doses beyond those administered in this study would be unlikely to provide additional benefit...
  14. ncbi request reprint Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease
    P F Smith
    Department of Pharmacy Practice, School of Pharmacy, State University of New York at Buffalo, 14260, USA
    Ann Pharmacother 33:1329-35. 1999
    ..To review information related to the accuracy of vancomycin serum drug concentrations in patients with end-stage renal disease, focusing on available assays and mechanisms of cross-reactivity...
  15. ncbi request reprint Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 1:473-85. 2005
    ..This review provides an updated summary of pharmacokinetic interactions with NNRTIs...
  16. ncbi request reprint Drug interactions between proton pump inhibitors and antiretroviral drugs
    Sarah M McCabe
    Associate Dean, Clinical Education and Research, University of Buffalo, Department of Pharmacy Practice, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 3:197-207. 2007
    ..This review summarizes the current knowledge on the interactions between proton pump inhibitors and antiretrovirals, and makes recommendations for the coadministration of proton pump inhibitors...
  17. ncbi request reprint Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate
    Patrick F Smith
    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, New York 14260, USA
    J Clin Pharmacol 42:658-61. 2002
    ..It was concluded that there is no clinically significant effect of a high-fat meal on the pharmacokinetics of either (-) or (+) dOTC when administered orally as a racemic mixture...
  18. ncbi request reprint Treating mammalian bite wounds
    P F Smith
    The State University of New York at Buffalo, School of Pharmacy, Department of Pharmacy Practice, Buffalo, New York 14260, USA
    J Clin Pharm Ther 25:85-99. 2000
    ..Close clinical follow-up is recommended to minimize the risk of late complications...
  19. pmc Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States
    Biochem Pharmacol 73:1280-7. 2007
    ..Intratumoral total Se concentration was not found to be predictive of the combination therapy response rates. There is a critical need to develop a method to measure the active metabolite of MSC, rather than total Se...
  20. ncbi request reprint A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Cancer Res 12:1237-44. 2006
    ..We conducted a phase I study to determine the maximum tolerated dose (MTD) of irinotecan with fixed, nontoxic high dose of selenomethionine...
  21. ncbi request reprint S-phase modulation by irinotecan: pilot studies in advanced solid tumors
    N Ramnath
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Chemother Pharmacol 56:447-54. 2005
    ..Lesser increases were seen with 40 and 60 mg/m(2). CPT-11 followed 24 h later by 5-FU 400 mg/m(2) per week for 4 weeks was well tolerated. In the study of CPT-11 followed by GEM 1000 mg/m(2), 60 mg/m(2) of CPT-11 was the MTD...
  22. ncbi request reprint Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation
    Julie M Bullock
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Ther Drug Monit 28:62-6. 2006
    ..All limited sampling models tested were unbiased in their results, and a 4-sample scheme proved to adequately characterize busulfan pharmacokinetics, and should allow for a reduced sampling frequency for therapeutic drug monitoring...
  23. ncbi request reprint A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Chemother Pharmacol 62:499-508. 2008
    ..We conducted a phase I study to determine the recommended dose of selenomethionine (SLM) in combination with irinotecan that consistently results in a protective plasma selenium (Se) concentrations > 15 microM after 1 week of SLM loading...
  24. pmc Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection
    Patrick F Smith
    Hoffman La Roche Inc, Clinical Pharmacology, Nutley, NJ 07110 1199, USA
    Antimicrob Agents Chemother 51:3574-81. 2007
    ..45 log(10), with individual patients having reductions of greater than 0.7 log(10). No bevirimat resistance mutations were detected during the course of the study...
  25. doi request reprint Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects
    Ying Jun Cao
    Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21287 5554, USA
    Pharmacotherapy 28:863-74. 2008
    ..To compare steady-state pharmacokinetics and pharmacodynamics of methadone enantiomers when coadministered with fosamprenavir 700 mg-ritonavir 100 mg twice/day...
  26. ncbi request reprint Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir
    Elinore F McCance-Katz
    Virginia Commonwealth University, Richmond, USA
    Clin Infect Dis 43:S235-46. 2006
    ..Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease...
  27. pmc Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi
    Brent M Booker
    The University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Applied Pharmacodynamics Labooratory, New York, USA
    Antimicrob Agents Chemother 49:1775-81. 2005
    ....
  28. ncbi request reprint Induction of imatinib metabolism by hypericum perforatum
    Patrick F Smith
    Blood 104:1229-30. 2004
  29. ncbi request reprint A grapefruit a day for patients infected with hepatitis C?
    Peter N Morcos
    Hepatology 47:2141-2; author reply 2142-3. 2008